MARY ELY: Open Payments
NPI 1639477425 · CLEVELAND, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$685 in 40 payments from 8 companies in 2025. Trend: 2023 $107 · 2024 $439 · 2025 $685
Food & beverage: $685
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 12 | $211 |
| E.R. Squibb & Sons, L.L.C. | 13 | $168 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| ABBVIE INC. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Corium, LLC | 2 | $26 |
| Lundbeck LLC | 1 | $26 |
Products named: Qelbree, COBENFY, Auvelity, VRAYLAR, CAPLYTA, ABILIFY ASIMTUFII, Azstarys, REXULTI.
Industry payments across MS — which companies pay providers there.
